Sex heterogeneity in pharmacogenetic smoking cessation clinical trials

Drug and Alcohol Dependence

Volumn 104, Issue SUPPL. 1, 2009, Pages

  Schnoll, Robert A ^a   Patterson, Freda ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Nicotine dependence; Pharmacogenetic; Sex; Smoking cessation

Indexed keywords

AMFEBUTAMONE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; DOPAMINE 2 RECEPTOR; DOPAMINE 4 RECEPTOR; MU OPIATE RECEPTOR; NICOTINE GUM; NICOTINE PATCH; NOSE SPRAY; PLACEBO; VENLAFAXINE;

CLINICAL TRIAL; GENDER; GENETIC VARIABILITY; HUMAN; NICOTINE REPLACEMENT THERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT RESPONSE;

BUPROPION; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; PHARMACOGENETICS; SEX CHARACTERISTICS; SEX FACTORS; SMOKING; SMOKING CESSATION;

EID: 68849126508     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.11.012     Document Type: Review

References (79)

1. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., Golden R.N., Martin P., Potter W.Z., Richelson E., and Sulser F. Bupropion: a review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56 (1995) 395-401
2. Balfour D.J. Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 413-421
3. Benowitz N.L., Lessov-Schlager C.N., Swan G., and Jacob III P. Female sex and oral contraceptive use accelerate nicotine metabolism. Clin. Pharmacol. Ther. 79 (2006) 480-488
4. Berrettini W.H., Wileyto E.P., Epstein L., Restine S., Hawk L., Shields P., Niaura R., and Lerman C. Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol. Psychiatry 61 (2007) 111-118
5. Beutner K.R., and Tyring S. Human papillomavirus and human disease. Am. J. Med. 102 (1997) 9-15
6. Bierut, L.J., in press. Genetics and smoking among women. Drug Alcohol Depend.
7. Boyle, P., Leon, M.E., Maisonneuve, P., Autier, P., 2003. Cancer control in women. Update. Int. J. Gynaecol. Obstet. 83 (Suppl. 1), 179-202.
8. Broms U., Silventoinen K., Madden P.A., Heath A.C., and Kaprio J. Genetic architecture of smoking behavior: a study of Finnish adult twins. Twin Res. Hum. Genet. 9 (2006) 64-72
9. Cepeda-Benito A., Reynoso J.T., and Erath S. Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women. J. Consult. Clin. Psychol. 72 (2004) 712-722
10. Cinciripini P., Wetter D., Tomlinson G., Tsoh J., De Moor C., Cinciripini L., and Minna J. The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood. Nicotine Tob. Res. 6 (2004) 229-240
11. Colilla S., Lerman C., Shields P.G., Jepson C., Rukstalis M., Berlin J., DeMichele A., Bunin G., Strom B.L., and Rebbeck T.R. Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenet. Genom. 15 (2005) 393-398
12. Cooper T.V., DeBon M., Stockton M., Klesges R.C., Steenbergh T.A., Sherrill-Mittleman D., Jennings L.C., and Johnson K.C. Correlates of adherence with transdermal nicotine. Addict. Behav. 29 (2004) 1565-1578
13. Dahl J.P., Jepson C., Levenson R., Wileyto E.P., Patterson F., Berrettini W.H., and Lerman C. Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence. Pharmacogenom. J. 6 (2006) 194-199
14. David S.P., Brown R.A., Papandonatos G.D., Kahler C.W., Lloyd-Richardson E.E., Munafò M.R., Shields P.G., Lerman C., Strong D., McCaffery J., and Niaura R. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob. Res. 9 (2007) 821-833
15. David S.P., Strong D.R., Munafò M.R., Brown R.A., Lloyd-Richardson E.E., Wileyto P.E., Evins E.A., Shields P.G., Lerman C., and Niaura R. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob. Res. 9 (2007) 1251-1257
16. David S.P., Munafò M.R., Murphy M.F., Walton R.T., and Johnstone E.C. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine Tob. Res. 9 (2007) 225-231
17. David S.P., Munafò M.R., Murphy M.F.G., Proctor M., Walton R.T., and Johnstone E.C. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenom. J. 8 (2008) 122-128
18. Giovino G.A. Epidemiology of tobacco use in the US. Oncogene 21 (2002) 7326-7340
19. Hamilton A.S., Lessov-Schlaggar C.N., Cockburn M.G., Unger J.B., Cozen W., and Mack T.M. Gender differences in determinants of smoking initiation and persistence in California twins. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 1189-1197
20. Hardie T.L., Moss H.B., and Lynch K.G. Genetic correlations between smoking initiation and smoking behaviors in a twin sample. Addict. Behav. 31 (2006) 2030-2037
21. Hughes, J., Stead, L., Lancaster, T., 2004. Antidepressants for smoking cessation. Cochr. Database Syst. Rev., CD000031.
22. Hurt R.D., Sachs D.P., Glover E.D., Offord K.P., Johnstone J.A., Dale L.C., Khayrallah M.A., Schroeder D.R., Glover P.N., Sullivan C.R., Croghan I.T., and Sullivan P.M. A comparison of sustained-release bupropion and placebo for smoking cessation. N. Engl. J. Med. 337 (1997) 1195-1202
23. Hutchison K.E., Allen D., Filbey F.M., Jepson C., Lerman C., Benowitz N.L., Stitzel J., Bryan A., McGeary J., and Haughey H. CHRNA4 and tobacco dependence: from gene regulation to treatment outcome. Arch. Gen. Psychiatry 64 (2007) 1078-1086
24. 108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 1065-1069
25. Johnstone E., Yudkin P.L., Hey K., Roberts S.J., Welch S.J., Murphy M.F., Griffiths S.E., and Walton R.T. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14 (2004) 83-90
26. Killen J.D., Fortmann S.P., Murphy G.M., Hayward C., Arredondo C., Cromp D., Celio M., Abe L., Wang Y., and Schatzberg A.F. Extended treatment with bupropion SR for cigarette smoking cessation. J. Consult. Clin. Psychol. 74 (2006) 286-294
27. Killen J.D., Fortmann S., Varady A., and Kraemer H.C. Do men outperform women in smoking cessation trials? Maybe, but not by much. Exp. Clin. Psychopharmacol. 10 (2002) 295-301
28. Kirchheiner J., Klein C., Meineke I., Sasse J., Zanger U.M., Murdter T.E., Roots I., and Brockmoller J. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13 (2003) 619-626
29. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., and Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6 (1996) 243-250
30. Lee A.M., Jepson C., Hoffmann E., Epstein L., Hawk L.W., Lerman C., and Tyndale R.F. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biol. Psychiatry 62 (2007) 635-641
31. Lerman C., Jepson C., Wileyto E.P., Epstein L.H., Rukstalis M., Patterson F., Kaufmann V., Restine S., Hawk L., Niaura R., and Berrettini W. The role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31 (2006) 231-242
32. Lerman C., Roth D., Kaufmann V., Audrain J., Hawk L., Liu A., Niaura R., and Epstein L. Mediating mechanisms for the impact of bupropion in smoking cessation treatment. Drug Alcohol Depend. 67 (2002) 219-223
33. Lerman C., Schnoll R.A., and Munafò M. Genetics and smoking cessation: improving outcomes in smokers at risk. Am. J. Prev. Med. 33 (2007) S398-S405
34. Lerman C., Shields P.G., Wileyto E.P., Audrain J., Hawk Jr. L.H., Pinto A., Kucharski S., Krishnan S., Niaura R., and Epstein L.H. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 22 (2003) 541-548
35. Lerman C., Shields P.G., Wileyto E.P., Audrain J., Pinto A., Hawk L., Krishnan S., Niaura R., and Epstein L. Pharmacogenetic investigation of smoking cessation treatment. Pharmacogenetics 12 (2002) 627-634
36. Lerman C., Tyndale R., Patterson F., Wileyto E.P., Shields P.G., Pinto A., and Benowitz N. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther. 79 (2006) 600-608
37. Lerman C., Wileyto E.P., Patterson F., Rukstalis M., Audrain-McGovern J., Restine S., Shields P.G., Kaufmann V., Redden D., Benowitz N., and Berrettini W.H. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenom. J. 4 (2004) 184-192
38. Li M.D., Cheng R., Ma J.Z., and Swan G.E. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male & female adult twins. Addict 98 (2003) 23-31
39. Malaiyandi V., Sellers E.M., and Tyndale R.F. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin. Pharmacol. Ther. 77 (2005) 145-158
40. Miksys S., Lerman C., Shields P.G., Mash D.C., and Tyndale R.F. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45 (2003) 122-132
41. Mills R.H., Sohn R.K., and Micevych P.E. Estrogen-induced mu-opioid receptor internalization in the medial preoptic nucleus is mediated via neuropeptide Y-Y1 receptor activation in the arcuate nucleus of female rats. J. Neurosci. 24 (2004) 947-955
42. Munafò M., Bradburn M., Bowes L., and David S. Are there sex differences in transdermal nicotine replacement therapy patch efficacy? A meta-analysis. Nicotine Tob. Res. 6 (2004) 769-776
43. Munafò M.R., Elliot K.M., Murphy M.F., Walton R.T., and Johnstone E.C. Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenom. J. 7 (2007) 353-361
44. 108/158Met genotype with smoking cessation. Pharmacogenet. Genom. 18 (2008) 121-128
45. Munafò M.R., Johnstone E.C., Wileyto E.P., Shields P.G., Elliot K.M., and Lerman C. Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 398-400
46. Munro, C.A., McCaul, M,E., Wong, D.F., Oswald, L.M., Zhou, Y., Brasic J., Kuwabara, H., Kumar, A., Alexander, M., Ye, W., Wand, G.S., 2006. Sex differences in striatal dopamine release in healthy adults. Biol. Psychiatry 59, 966-974.
47. Nestler E.J. Is there a common molecular pathway for addiction?. Nat. Neurosci. 8 (2005) 1445-1449
48. Neville M.J., Johnstone E.C., and Walton R.T. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat. 23 (2004) 540-545
49. O'Gara C., Stapleton J., Sutherland G., Guindalini C., Neale B., Breen G., and Ball D. Dopamine transporter polymorphisms are associated with short-term response to smoking cessation treatment. Pharmacogenet. Genom. 17 (2007) 61-67
50. Osler M., Holst C., Prescott E., and Sorensen T.I. Influence of genes and family environment on adult smoking behavior assessed in an adoption study. Genet. Epidemiol. 21 (2001) 193-200
51. Patel J.D., Bach P.B., and Kris M.G. Lung cancer in US women: a contemporary epidemic. JAMA 291 (2004) 1763-1768
52. Perkins K. Obstacles to determining individual differences in the efficacy of smoking cessation medications. Nicotine Tob. Res. 6 (2004) 765-767
53. Perkins K., Donny E., and Caggiula A.R. Sex differences in nicotine effects and self-administration: review of human and animal evidence. Nicotine Tob. Res. 1 (1999) 301-315
54. Perkins K.A., and Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob. Res. 10 (2008) 1245-1250
55. Perkins, K.A., in press. Unique behavioral and pharmacological effects of smoking among women. Drug Alcohol Depend.
56. Pohjalainen T., Rinne J.O., Nagren K., Lehikoinen P., Anttila K., Syvalahti E.K., and Hietala J. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 3 (1998) 256-260
57. Pontieri F., Tanda G., Orzi F., and Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382 (1996) 255-257
58. Ray R., Jepson C., Patterson F., Strasser A., Rukstalis M., Perkins K., Lynch K.G., O'Malley S., Berrettini W.H., and Lerman C. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology 188 (2006) 355-363
59. Ray R., Jepson C., Wileyto E.P., Dahl J.P., Patterson F., Rukstalis M., Pinto A., Berrettini W., and Lerman C. Genetic variation in mu opioid receptor interacting proteins and smoking cessation in a nicotine replacement therapy trial. Nicotine Tob. Res. 9 (2007) 1237-1241
60. Robinson J.D., Lam C.Y., Minnix J.A., Wetter D.W., Tomlinson G.E., Minna J.D., Chen T.T.L., and Cinciripini P.M. The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. Pharmacogenom. J. 7 (2007) 266-274
61. Scharf D., and Shiffman S. Are there gender differences in smoking cessation, with and without bupropion? Pooled- and meta-analyses of clinical trials of Bupropion SR. Addict 99 (2004) 1462-1469
62. Shield A.J., Thomae B.A., Eckloff B.W., Wieben E.D., and Weinshilboum R.M. Human catechol-O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol. Psychiatry 9 (2004) 151-160
63. Slemmer J.E., Martin B.R., and Damaj M.I. Bupropion is a nicotinic antagonist. J. Pharmacol. Exp. Ther. 295 (2000) 321-327
64. Schnoll R.A., Johnson T., and Lerman C. Genetic influences on smoking initiation, nicotine dependence, and smoking cessation. Curr. Psychiatr. Rep. 9 (2007) 349-357
65. Schnoll R.A., and Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin. Emerg. Drugs 11 (2006) 429-444
66. Stead L., Bullen R.P., Mant C., and Lancaster T. Nicotine replacement therapy for smoking cessation. Cochr. Database Syst. Rev. 21 (2008) CD000146
67. Sullivan P.F., and Kendler K.S. The genetic epidemiology of smoking. Nicotine Tob. Res. 1 (1999) S51-S57
68. Swan G., Jack L.M., Valdes A.M., Ring H.Z., Ton C.C., Curry S.J., and McAfee T. Joint effect of dopaminergic genes on likelihood of smoking following treatment with bupropion SR. Health Psychol. 26 (2007) 361-368
69. Swan G.E., Valdes A.M., Ring H.Z., Khroyan T.V., Jack L.M., Ton C.C., Curry S.J., and McAfee T. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenom. J. 5 (2005) 21-29
70. Thompson J., Thomas N., Singleton A., Piggott M., Lloyd S., Perry E.K., Morris C.M., Perry R.H., Ferrier I.N., and Court J.A. D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7 (1997) 479-484
71. Uhl, G.R., in press. Molecular genetics of smoking cessation success: relationships with results from other phenotypes. Drug Alcohol Depend.
72. Wallace, J.M., in press. Understanding racial and ethnic influences on smoking among women. Drug Alcohol Depend.
73. Wetter D.W., Fiore M.C., Young T.B., McClure J.B., de Moor C.A., and Baker T.B. Gender differences in response to nicotine replacement therapy: objective and subjective indexes of tobacco withdrawal. Exp. Clin. Psychopharmacol. 7 (1999) 135-144
74. Wileyto E.P., Patterson F., Niaura R., Epstein L., Brown R., Audrain-McGovern J., Hawk L., and Lerman C. Recurrent event analysis of lapse and recovery in a smoking cessation clinical trial utilizing bupropion. Nicotine Tob. Res. 7 (2005) 257-268
75. Xian H., Scherrer J., Madden P., Lyons M.J., Tsuang M., True W.R., and Eisen S.A. The heritability of failed smoking cessation and nicotine withdrawal in twins who smoked and attempted to quit. Nicotine Tob. Res. 5 (2003) 245-254
76. Xian H., Scherrer J., Madden P., Lyons M.J., Tsuang M., True W.R., and Eisen S.A. Latent class typology of nicotine withdrawal: genetic contributions and association with failed smoking cessation and psychiatric disorders. Psychol. Med. 35 (2005) 409-419
77. Yudkin P., Munafò M., Hey K., Roberts S., Welch S., Johnstone E., Murphy M., Griffiths S., and Walton R. Effectiveness of nicotine patches in relation to genotype in women vs. men: randomized controlled trial. Br. Med. J. 328 (2004) 989-990
78. Zhang Y., Wang D., Johnson A.D., Papp A.C., and Sadee W. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 280 (2005) 32618-32624
79. Zubieta J.K., Dannals R.F., and Frost J.J. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am. J. Psychiatry 156 (1999) 842-848